Over the past two decades, trials of citicoline for treatment of acute stroke have produced conflicting results. A recent large clinical trial of citicoline in acute stroke suggests a lack of efficacy of this therapy, seemingly signalling the end to the citicoline saga.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Neuron-secreted NLGN3 ameliorates ischemic brain injury via activating Gαi1/3-Akt signaling
Cell Death & Disease Open Access 25 October 2023
-
Oxygen glucose deprivation/re-oxygenation-induced neuronal cell death is associated with Lnc-D63785 m6A methylation and miR-422a accumulation
Cell Death & Disease Open Access 30 September 2020
-
Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues
CNS Drugs Open Access 07 February 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aronowski, J., Strong, R. & Grotta, J. C. Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. Neurol. Res. 18, 570–574 (1996).
Tazaki, Y. et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 19, 211–216 (1988).
Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E. & Sabounjian, L. A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology 49, 671–678 (1997).
Clark, W. M. et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 30, 2592–2597 (1999).
Warach, S. et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann. Neurol. 48, 713–722 (2000).
Clark, W. M., Wechsler, L R., Sabounjian, L. A. & Schwiderski, U. E. A phase III randomized efficacy trial of 2000mg citicoline in acute ischemic stroke patients. Neurology 57, 1595–1602 (2001).
Davalos, A. et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet http://dx.doi.org/10.1016/S0140-6736(12)60813-7.
[No authors listed]. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581–1587 (1995).
Davalos, A. et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 33, 2850–2857 (2002).
Fresta, M., Puglisi, G., Di Giacomo, C. & Russo, A. Liposomes as in vivo carriers for citicoline: effects on rat cerebral post-ischaemia reperfusion. J. Pharm. Pharmacol. 46, 974–981 (1994).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Clark, W., Clark, T. Treatment for acute stroke—the end of the citicoline saga. Nat Rev Neurol 8, 484–485 (2012). https://doi.org/10.1038/nrneurol.2012.166
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.166
This article is cited by
-
Neuron-secreted NLGN3 ameliorates ischemic brain injury via activating Gαi1/3-Akt signaling
Cell Death & Disease (2023)
-
Oxygen glucose deprivation/re-oxygenation-induced neuronal cell death is associated with Lnc-D63785 m6A methylation and miR-422a accumulation
Cell Death & Disease (2020)
-
Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues
CNS Drugs (2014)
-
Citicoline in stroke and TBI clinical trials
Nature Reviews Neurology (2013)
